Press release
United States Narcolepsy Therapeutics Market (2025) | Market Report include - Narcolepsy Drug, Narcolepsy Type 1, Central Nervous System Stimulants, Orexin Receptor Agonists, Sleep Disorder Treatment
Narcolepsy Therapeutics Maket Size 2025
narcolepsy therapeutics market reached US$ 2.93 billion in 2023, with a rise to US$ 3.19 billion in 2024, and is expected to reach US$ 6.98 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.
Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/narcolepsy-therapeutics-market?kb
United States: Recent Industry Developments
✅ March 2026: Jazz Pharmaceuticals plc expanded commercialization initiatives for narcolepsy therapies focused on excessive daytime sleepiness and cataplexy management.
✅ February 2026: Harmony Biosciences Holdings, Inc. strengthened research activities for next-generation wake-promoting therapies targeting improved long-term patient outcomes.
✅ January 2026: Axsome Therapeutics, Inc. advanced clinical development programs for novel CNS therapies with potential applications in sleep-wake disorders including narcolepsy.
✅ December 2025: Avadel Pharmaceuticals plc increased focus on extended-release nighttime treatment formulations designed to improve sleep continuity in narcolepsy patients.
Download Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/narcolepsy-therapeutics-market?kb
List of Key Players 2026:
Jazz Pharmaceuticals, Inc., Avadel, Apotex Inc., Novartis AG, and Harmony Biosciences
Key Strategic Growth Forecast Projections 2026:
The Global Narcolepsy Therapeutics Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
✅ May 2026: Eli Lilly announced plans to acquire Centessa Pharmaceuticals to strengthen its neuroscience and sleep disorder portfolio, expanding development of orexin receptor 2 agonists for narcolepsy and excessive daytime sleepiness.
✅ February 2026: Harmony Biosciences reported strong commercial growth for WAKIX®, with 2026 revenue guidance projected to exceed USD 1 billion, while advancing next-generation pitolisant formulations and orexin-2 agonist programs.
✅ January 2026: Axsome Therapeutics advanced AXS-12 toward regulatory submission for narcolepsy treatment following positive FDA pre-NDA feedback, strengthening its late-stage CNS therapeutics pipeline.
✅ January 2026: Harmony Biosciences continued expansion of its narcolepsy franchise through ongoing Phase 3 programs and development of next-generation formulations designed to extend long-term market exclusivity.
✅ November 2025: Centessa Pharmaceuticals reported positive Phase 2a data for ORX750, demonstrating strong wakefulness improvements in narcolepsy type 1 and type 2 patients, supporting advancement toward registrational studies.
✅ October 2025: Alkermes strengthened its position in sleep medicine through the acquisition of Avadel Pharmaceuticals, expanding its narcolepsy portfolio with Lumryz® for cataplexy and excessive daytime sleepiness treatment.
How Our Market Research Process Works:
The global Narcolepsy Therapeutics Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Narcolepsy Therapeutics adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• May 2026: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for US$4.1 billion, strengthening its neuroscience and rare neurological disorders portfolio, including sleep-related therapies.
• March 2026: Eli Lilly and Company announced the acquisition of Centessa Pharmaceuticals for up to US$7.8 billion to expand its narcolepsy and sleep-wake disorder pipeline with orexin-targeting therapies.
• February 2026: Alkermes plc completed the acquisition of Avadel Pharmaceuticals, adding narcolepsy treatment LUMRYZ® and expanding its sleep medicine business.
• October 2025: Alkermes plc announced a US$2.1 billion deal to acquire Avadel Pharmaceuticals to strengthen its narcolepsy therapeutics portfolio and enter the sleep medicine market.
Request Strategic Market Customization: https://datamintelligence.com/customize/narcolepsy-therapeutics-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company Limited enhanced neuroscience research collaborations targeting innovative therapies for rare neurological and sleep disorders.
✅ February 2026: Astellas Pharma Inc. expanded CNS therapeutic research programs focused on improving patient quality of life in sleep-related disorders.
✅ January 2026: Eisai Co., Ltd. strengthened development efforts for neurological disorder therapeutics leveraging advanced neuropharmacology platforms.
✅ December 2025: Sumitomo Pharma Co., Ltd. accelerated partnerships in CNS drug innovation to support next-generation narcolepsy and sleep disorder treatment development.
Major Segments Opportunity 2026:
By Disease Type: Narcolepsy Type 1, Narcolepsy Type 2
By Therapeutic Type: Central Nervous System Stimulants, Central Nervous System Depressants, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Regional Growth Intelligence for Market:
⇥ North America: 42.1% - Leads the narcolepsy therapeutics market due to advanced healthcare infrastructure, strong diagnosis rates, and increasing adoption of novel sleep disorder treatments.
⇥ Europe: 24.3% - Growth supported by rising awareness of sleep disorders, favorable reimbursement policies, and expanding neurological treatment access.
⇥ Asia-Pacific: 19.5% - Fastest-growing regional market driven by improving healthcare access, growing patient population, and increasing investments in sleep medicine.
⇥ Latin America: 7.1% - Market expansion fueled by improving healthcare facilities and increasing awareness of narcolepsy diagnosis and treatment.
⇥ Middle East & Africa: 7.0% - Emerging demand supported by healthcare modernization initiatives and rising focus on neurological disorder management.
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=narcolepsy-therapeutics-market?kb
Market Drivers 2026:
Rapid advancements in orexin receptor agonists and next-generation wakefulness-promoting therapies improving treatment efficacy and patient compliance.
Increasing development of non-stimulant therapies and extended-release formulations expanding treatment options for narcolepsy management.
Growing integration of digital sleep monitoring technologies and AI-based diagnostic tools enhancing early detection and personalized treatment approaches.
Expansion of clinical research activities focused on rare neurological disorders creating new growth opportunities in the Narcolepsy Therapeutics market.
Rising strategic collaborations among pharmaceutical companies, research institutes, and sleep disorder centers strengthening drug development pipelines.
Continuous innovation in CNS-targeted therapeutics and precision medicine approaches improving safety profiles and therapeutic outcomes.
Increasing focus on awareness campaigns, patient advocacy programs, and sleep health education accelerating diagnosis and treatment adoption worldwide.
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Narcolepsy Therapeutics Market (2025) | Market Report include - Narcolepsy Drug, Narcolepsy Type 1, Central Nervous System Stimulants, Orexin Receptor Agonists, Sleep Disorder Treatment here
News-ID: 4511756 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Electric Vehicle Fluids Market Expands Rapidly as 20 Million EV Sales Increase T …
Market Size and Growth 2026
Global electric vehicle sales surpassed 20 million units in 2025, up from 17.3 million in 2024, according to Castrol, expanding the addressable market for specialized transmission fluids, thermal-management fluids, greases, and other EV-specific formulations. The increase in EV volumes is strengthening demand for fluids engineered for high-voltage systems, fast charging, lower energy losses, and battery thermal control. In November 2025, Castrol also partnered with LION Smart…
Smart Coatings Market Advances as AkzoNobel Invests €7.5 Million in Next-Gener …
AkzoNobel inaugurated a €7.5 million innovation laboratory in Sassenheim, Netherlands, in September 2026, strengthening its global R&D capabilities for powder coatings. The facility is focused on developing next-generation, solvent-free and energy-efficient coatings, including lower-temperature curing technologies designed to reduce energy consumption while improving coating performance, product lifetime and material efficiency. The investment adds dedicated research capacity to an area closely aligned with smart-coating demand for multifunctional, durable and sustainability-oriented surface…
Cultured Meat Market Gains Scale with Meatly's £10.4 Million Investment in 20,0 …
Market Size and Growth 2026
The global Cultured Meat market reached an estimated US$ 487.6 million in 2025 and is expected to reach US$ 2.96 billion by 2035, growing with a CAGR of 19.8% during the forecast period 2026-2035.
The cultured meat market is moving toward larger-scale commercial production as Meatly secured £10.4 million in Series A funding in May 2026 to develop a 20,000-liter bioreactor facility in London, described by the…
Superhydrophobic Coatings Market Gains Traction as P2i Secures €8 Million Inve …
P2i secured an initial €8 million investment from Jolt Capital in 2025, with Jolt taking a controlling stake in the company. The funding is supporting the expansion and diversification of P2i's protective nanotechnology platform, which has been deployed on more than one billion devices. The development strengthens commercial opportunities for water-repellent and barrier coatings across electronics, automotive, medical and industrial applications, while increasing demand for scalable, durable surface-treatment technologies.
The…
More Releases for Pharma
Schizophrenia Market Gains Momentum with Expanding Pipeline and Investment Poten …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed…
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
